Skip to main content

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Publication ,  Journal Article
Farahany, NA; Benatar, M; Wuu, J; Andersen, PM; Bucelli, RC; Andrews, JA; Otto, M
Published in: Neurotherapeutics
2022

Duke Scholars

Published In

Neurotherapeutics

Publication Date

2022

Volume

19

Issue

4

Start / End Page

1248 / 1258

Related Subject Headings

  • Superoxide Dismutase-1
  • Superoxide Dismutase
  • RNA, Messenger
  • Oligonucleotides, Antisense
  • Neurology & Neurosurgery
  • Neurodegenerative Diseases
  • Mutation
  • Humans
  • Biomarkers
  • Amyotrophic Lateral Sclerosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farahany, N. A., Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., & Otto, M. (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258.
Farahany, Nita A., Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, and Markus Otto. “Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.” Neurotherapeutics 19, no. 4 (2022): 1248–58.
Farahany NA, Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022;19(4):1248–58.
Farahany NA, Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022;19(4):1248–1258.

Published In

Neurotherapeutics

Publication Date

2022

Volume

19

Issue

4

Start / End Page

1248 / 1258

Related Subject Headings

  • Superoxide Dismutase-1
  • Superoxide Dismutase
  • RNA, Messenger
  • Oligonucleotides, Antisense
  • Neurology & Neurosurgery
  • Neurodegenerative Diseases
  • Mutation
  • Humans
  • Biomarkers
  • Amyotrophic Lateral Sclerosis